Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Por Stenlöf, K, Cefalu, W T, Kim, K-A, Alba, M, Usiskin, K, Tong, C, Canovatchel, W, Meininger, G
Publicado em 2013

Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease

Por Monteleone, G., Di Sabatino, A., Ardizzone, S., Pallone, F., Usiskin, K., Zhan, X., Rossiter, G., Neurath, M. F.
Publicado no Aliment Pharmacol Ther (2016)

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

Por Yale, J-F, Bakris, G, Cariou, B, Yue, D, David-Neto, E, Xi, L, Figueroa, K, Wajs, E, Usiskin, K, Meininger, G
Publicado em 2013

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

Por Wilding, J P H, Charpentier, G, Hollander, P, González-Gálvez, G, Mathieu, C, Vercruysse, F, Usiskin, K, Law, G, Black, S, Canovatchel, W, Meininger, G
Publicado no Int J Clin Pract (2013)